Scarica l'app Stockscreener
2.69
2.18%
-0.06
Acelyrin Inc Borsa (SLRN) Ultime notizie
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy - BioSpace
Acelyrin stock in focus after poison pill (SLRN:NASDAQ) - Seeking Alpha
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell -March 13, 2025 at 08:09 am EDT - Marketscreener.com
Acelyrin adopts rights plan in response to Tang Capital stake - Investing.com India
Acelyrin adopts rights plan in response to Tang Capital stake By Investing.com - Investing.com South Africa
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - The Manila Times
Acelyrin: Potential Buyout Led By Concentra Biosciences (NASDAQ:SLRN) - Seeking Alpha
How a skin drug trial could help Peninsula biotech pull off key merger - The Business Journals
Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger - TipRanks
New York State Common Retirement Fund Lowers Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
10 Best Micro Cap Stocks to Buy Now - Insider Monkey
Acelyrin falls as Acelyrin reaffirms deal commitment - MSN
Acelyrin rebuffs Concentra bid, believing Alumis option better - The Pharma Letter
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger - BioSpace
Acelyrin To Proceed With Alumis Merger, Spurn Concentra Bid - insights.citeline.com
Sector Update: Health Care Stocks Lower Tuesday Afternoon -March 04, 2025 at 02:01 pm EST - Marketscreener.com
Acelyrin Reaffirms Merger Deal With Alumis -March 04, 2025 at 10:13 am EST - Marketscreener.com
Acelyrin stock falls on Acelyrin deal commitment (SLRN:NASDAQ) - Seeking Alpha
Alumis Inc. Announces Merger with ACELYRIN, Inc. - TipRanks
Acelyrin says Concentra indication not expected to result in superior proposal - TipRanks
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - The Manila Times
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger - The Manila Times
Alumis Inc. and ACELYRIN, Inc. Confirm Commitment to All-Stock Merger to Create Leading Biopharma Company in Immune-Mediated Diseases - Nasdaq
Alumis And Acelyrin Reaffirm Strategic And Financial Rationale Of Proposed Merger -March 04, 2025 at 09:06 am EST - Marketscreener.com
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not ... - Eagle-Tribune
Can This Biopharma Merger's $737M War Chest Transform Immune Disease Treatment? - StockTitan
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Notifies Acelyrin, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSLRN - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2024 in Acelyrin LawsuitSLRN - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Acelyrin, Inc. (SLRN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report - BioCentury
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week - NewsBreak
Activist investor threatens drug maker's merger plans with L.A. biotech - L.A. Business First
Activist investor threatens Peninsula drug maker's merger plansSan Francisco Business Times - The Business Journals
Concentra Biosciences, LLC made an Unsolicited Indication of Interest to acquire Acelyrin, Inc. from a group of shareholders for approximately $310 million. - Marketscreener.com
ACELYRIN shares surge on buyout interest By Investing.com - Investing.com Nigeria
ACELYRIN shares surge on buyout interest - Investing.com
Acelyrin Receives Unsolicited Buyout Offer From Concentra Biosciences -February 21, 2025 at 04:38 am EST - Marketscreener.com
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences - TipRanks
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):